Related Articles
Important factors for achieving survival of five years or more in non‑small cell lung cancer patients with distant metastasis
First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status
Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine‑refractory pancreatic cancer patients
Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene
Efficacy of second‑line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non‑small cell lung cancer without epidermal growth factor receptor mutations